Understanding Insurance Coverage for Jakafi® (ruxolitinib)

IncyteCARES MAY BE ABLE TO HELP ELIGIBLE PATIENTS REDUCE CONCERNS ABOUT THEIR PRESCRIPTION DRUG COVERAGE AND THEIR COST FOR JAKAFI

You may have questions about the coverage of your Jakafi by your prescription drug plan. When you enroll in IncyteCARES, you can talk one-on-one with an oncology certified nurse to help you figure that out.

The program may also provide reimbursement support to you and your healthcare professional’s office. IncyteCARES nurses will provide information about prior authorizations and give guidance on appealing insurance denials or coverage restrictions, if needed. See below to find out how IncyteCARES can assist you with your insurance coverage questions about Jakafi.

IncyteCARES can help with insurance benefit verification for your Jakafi

IncyteCARES MAY BE ABLE TO PROVIDE INFORMATION ABOUT PRIOR AUTHORIZATIONS AND INSURANCE APPEALS

If needed, an IncyteCARES oncology certified nurse will work with eligible patients and healthcare professionals to provide information about prescription drug plan requirements that must be met to get access to Jakafi. Some plans may require a prior authorization, which means they will ask for more information from your healthcare professional before deciding how much you will need to pay for your Jakafi. IncyteCARES will work with your healthcare professional's office as the office responds to and provides this information to your plan.

In addition, if an insurance company says it will not pay for Jakafi, IncyteCARES can help you and your healthcare professional understand why coverage was denied and information about appealing the denial.

Based on patients diagnosed with an FDA-approved indication enrolled in IncyteCARES between June 2014 and June 2016:

95%

of prior authorizations were approved for Jakafi

IncyteCARES may be able to help with temporary access during insurance coverage delays

If you experience insurance coverage delays, IncyteCARES may be able to provide access to Jakafi. Eligible patients who have been prescribed Jakafi for an FDA-approved indication and who are experiencing an insurance coverage delay can receive a free supply of Jakafi after a proof of claims submission has been provided.

The free product is offered to eligible patients without any purchase contingency or other obligation. For more information, please contact IncyteCARES at 1-855-4-Jakafi (1-855-452-5234).

top-bar
bottom-bar
Have a comment or question about IncyteCARES?

We welcome your feedback.

 An IncyteCARES oncology certified nurse may contact me regarding my question or comment.

Understanding Insurance Coverage FAQs

How long does it take to find out my insurance coverage for Jakafi?

Insurance benefit verifications for Jakafi are completed in most cases within 2 business days of IncyteCARES' receipt of a completed enrollment submission. On occasion, some payers may require additional time to contact and obtain benefits; however, IncyteCARES will communicate any issues with obtaining benefits information with the office and/or the patient within 2 business days.

How often do my benefits need to be verified through IncyteCARES?

Participation in the IncyteCARES program is annual. That means every year you use IncyteCARES, you have to submit a new enrollment form and we have to perform a benefit verification and screen for financial assistance. The program will send correspondence to inform both you and your healthcare professional when the term of participation in the program is coming to an end and another enrollment form is needed.

If you are currently enrolled in IncyteCARES and have had a:

Change in insurance or

Life-changing event (loss of employment, change in income, loss of or change in prescription drug insurance coverage)

...please contact IncyteCARES so that we can verify your benefits or possibly provide additional services.

Indications and Usage

Jakafi is a prescription medicine used to treat people with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is also used to treat certain types of myelofibrosis.

Important Safety Information

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Skin cancers: Some people who take Jakafi have developed certain types of non-melanoma skin cancers. Tell your healthcare provider if you develop any new or changing skin lesions.

Increases in cholesterol: You may have changes in your blood cholesterol levels. Your healthcare provider will do blood tests to check your cholesterol levels during your treatment with Jakafi.

The most common side effects of Jakafi include: low platelet count, low red blood cell counts, bruising, dizziness, headache.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Tell your healthcare provider about any side effect that bothers you or that does not go away.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had tuberculosis (TB) or have been in close contact with someone who has TB, have or had hepatitis B, have or had liver or kidney problems, are on dialysis, had skin cancer, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider. Do not drink grapefruit juice while on Jakafi.

Women should not take Jakafi while pregnant or planning to become pregnant, or if breast-feeding.

Please see Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.